Última actualização :
14/12/2024
Infostab
Lista de compostos
Listas de leitura dos resumos de informação
Pesquise compatibilidades
Tabela de compatibilidade do site Y
Bibliografía
As equipas de investigação
valistab
poster
Conexões
patrocinadores
Autores
Manual do utilizador
Boletim de notícias
Tacrolimus
estrutura química
Bibliografía : Tacrolimus
tipo
publicação
2436
jornal
Jacobson PA, Johnson CE, West NJ, Foster JA.
Stability of tacrolimus in an extemporaneously compounded oral liquid
Am J Health-Syst Pharm 1997 ; 54: 178-180.
2789
jornal
Elefante A, Muindi J, West K, Dunford L, Abel S, Paplham P, Brown K, Hahn T, Padmanabhan S, Battiwalla M, McCarthy PL.
Long-term stability of a patient-convenient 1mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels.
Bone Marrow Transplantation 2006 ; 37, 8: 781-784.
3846
jornal
Polonini HC, Silva SL, Cunha CN, Brand?o MAF, Ferreira AO.
Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions.
Pharmazie 2016 71: 185?191.
3946
jornal
Friciu M, Zaraa S, Leclair G.
Stability of Extemporaneously Compounded Tacrolimus in Glass Bottles and Plastic Syringes
Can J Hosp Pharm 2017 ; 70,1 :51-53.
4177
jornal
Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A.
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4.
Int J Pharm Compound 2018 ;22,6:516-526
4673
jornal
Barrieu M, Chennell P, Yessaad M, Bouattour Y, Wasiak M, Jouannet M, Le Basle Y, Sautou V.
Physicochemical Stability of a Novel Tacrolimus Ophtalmic Formulation for the Treatment of Ophtalmic Inflammatory Diseases.
Pharmaceutics 2022 ;14,1:118
Mentions Légales
